AMIA responded to the latest USCDI Version 6 Draft. There are numerous recommendations including proposing ASTP/ONC create a roadmap to incorporate USCDI+ with future iterations of USCDI. AMIA also recommended incorporating Environmental Determinants of Health (EDOH) alongside Social Determinants of Health (SDOH) to provide a comprehensive view of factors influencing […]
AMIA joined more than 75 organizations representing a broad coalition of scientific, research, public health, and academic associations, urging greater transparency surrounding potential large-scale Reduction in Force (RIF) and reorganizations within federal agencies critical to the nation's scientific enterprise and public health infrastructure.
Through the Patient ID Now coalition, AMIA along with over 150 healthcare organizations urge Congress to remove Section 510 from the FY2026 Labor-HHS Appropriations bill, which bans funding for a national unique patient identifier. This outdated provision hinders patient safety, contributes to medical errors, and causes costly inefficiencies—totaling over $6.7 […]
AMIA joined Coalition for Health Funding’s letter, signed by over 500 health and research organizations, strongly opposing the Administration’s draft FY 2026 budget proposal for the Department of Health and Human Services (HHS), which includes a one-third cut to discretionary funding. The coalition warns such cuts would severely harm the […]
On April 23, 2025, AMIA joined over 100 organizations urging Congress to allocate at least $1.7 billion for the Advanced Research Projects Agency for Health (ARPA-H) in FY 2026, emphasizing the importance of maintaining its independence within the Department of Health and Human Services. ARPA-H, modeled after DARPA, has initiated […]
AMIA raised concerns about the evidence behind the HHS reorganization decisions and questions the exclusion of the Assistant Secretary for Technology Policy/Office of the National Coordinator of Health IT (ASTP). It highlights the importance of ASTP in securing patient data and supporting clinical care. AMIA also questioned the potential move […]
AMIA responded to the FDA's draft guidance on "Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations." We commended the FDA for its comprehensive approach to ensuring the safe and effective use of AI-enabled devices in healthcare. The comment letter emphasized the importance of transparency, bias control, and […]